Chamber-Specific Cardiomyocyte Subtypes Through Staged hPSC Differentiation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods struggle to generate appropriate cardiomyocyte subtypes from human pluripotent stem cells (hPSCs) for modeling cardiovascular diseases and developing therapeutic approaches, as different cardiovascular diseases target specific regions of the heart, requiring chamber-specific cell types.

Innovation Solution

A comprehensive protocol for differentiating human pluripotent stem cells into cardiomyocyte subtypes using staged manipulation of signaling pathways, including BMP4 and Activin A, to produce mesoderm cells and progenitor cells, which are then cultured under specific conditions to generate chamber-specific cardiomyocytes such as RVCMs, LVCMs, ACMs, AVCCMs, IFTCMs, and OFTCMs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If existing differentiation methods are used, then cardiomyocytes can be generated, but the ability to generate chamber-specific cardiomyocyte subtypes is insufficient

Engineering Contradiction:

Improveability to generate chamber-specific cardiomyocyte subtypesVSAvoidspecificity of cardiomyocyte subtypes

Core Design Contradiction:

Adaptability or versatilityVSManufacturing precision

Solution Approach 1:

The patent segments the differentiation process into distinct stages (mesoderm formation, cardiac progenitor specification, chamber-specific differentiation) and introduces stage-specific signaling molecules (BMP4, Activin A, Wnt inhibitors, retinoic acid) to guide cells through each transition. This staged manipulation enables precise generation of different cardiomyocyte subtypes (LVCMs, RVCMs, ACMs, OFTCMs) from a common hPSC starting population.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent systematically changes biochemical parameters (concentrations of BMP4, Activin A, Wnt inhibitors, retinoic acid) and temporal parameters (duration of exposure, sequential addition timing) to direct differentiation toward specific chamber fates. For example, varying BMP4 and Activin A ratios at different stages produces distinct mesoderm and progenitor populations that commit to specific ventricular or atrial lineages.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If staged manipulation of signaling pathways is implemented, then chamber-specific cardiomyocyte subtypes can be generated, but the protocol complexity increases

Engineering Contradiction:

Improvediversity of cardiomyocyte subtypes producedVSAvoiddifferentiation protocol complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent performs preliminary actions by first establishing mesoderm commitment using BMP4 and Activin A before introducing chamber-specific signaling manipulations. This preliminary mesoderm formation step creates a standardized intermediate population that can then be directed toward different chamber fates, simplifying the overall process by breaking it into manageable sequential stages rather than attempting simultaneous differentiation.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses intermediary cell states (mesoderm, cardiac progenitors) as transitional populations between hPSCs and final chamber-specific cardiomyocytes. These intermediary stages express specific markers (MESP1, CXCR4, ALDH1A2, CD1d) that allow monitoring and further manipulation, serving as controlled intermediate steps that reduce the complexity of direct differentiation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250320458A1Cardiomyocyte subtypes and methods of making and using

Publication Date: 2025.10.16 UNIV HEALTH NETWORK

AI summary

Cardiomyocyte subtypes, including first heart field (FHF) and second heart field (SHF) (e.g., anterior second heart field (aSHF) and posterior second heart field (pSHF)) cells, and methods of making and using such cells, are described.